Tu1321 VONOPRAZAN 10 OR 20 MG DEMONSTRATED SUPERIORITY OVER LANZOPRAZOLE 15 MG IN PREVENTING RELAPSE IN ASIAN PATIENTS WITH ENDOSCOPIC HEALING OF EROSIVE ESOPHAGITIS: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY

Xiao, Yinglian; Qian, Jiaming; Zhang, Shutian; Dai, Ning; Goh, Khean Lee; Chun, Hoon Jai; Chiu, Cheng-Tang; Chong, Chui Fung; Funao, Nobuo; Sakurai, Yuuichi; Chen, Minhu

doi:10.1016/s0016-5085(20)33328-x

Cited by 2 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 23 , 29 , 54 Thirty-four studies were RCTs, 10 – 14 , 19 – 23 , 32 – 35 , 38 , 42 – 44 , 46 , 52 , 54 , 55 , 57 , 60 , 61 , 63 , 72 , 74 , 77 , 80 , 83 , 85 , 86 , 89 24 cohort studies, 15 , 24 , 27 , 31 , 36 , 37 , 41 , 47 , 50 , 51 , 53 , 56 , 59 , 62 , 64 – 67 ,…”

Section: Resultsmentioning

confidence: 99%

“…These included studies which were published between 2015 and 2022. Seventy-four studies were conducted in Asia, 10–15,19–22,24–28,30–53,55–…”

Section: Resultsmentioning

confidence: 99%

“…Seventy-four studies were conducted in Asia, [10][11][12][13][14][15][19][20][21][22][24][25][26][27][28] and three in non-Asian countries. 23,29,54 Thirty-four studies were RCTs, [10][11][12][13][14][19][20][21][22][23][32][33][34][35]38,[42][43][44]46,52,54,55,57,60,61,63,72,74,77,80,83,85,86,89 24 cohort studies,…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

“…23,29,54 Thirty-four studies were RCTs, [10][11][12][13][14][19][20][21][22][23][32][33][34][35]38,[42][43][44]46,52,54,55,57,60,61,63,72,74,77,80,83,85,86,89 24 cohort studies, 15,24,27,31,36,37,41,47,50,51,53,56,59,62,[64][65]…”

Section: Study Selection and Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis

Bai

Shang

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

Background: Vonoprazan, a novel acid-suppressive drug, is non-inferior to proton pump inhibitors (PPIs) for the management of gastric acid-related diseases. However, the safety of vonoprazan has not been systematically evaluated yet. Objectives: To elucidate the incidence and type of adverse events (AEs) in patients taking vonoprazan. Design: Systematic review and meta-analysis. Data sources and methods: PubMed, EMBASE, and Cochrane Library databases were searched for all studies reporting the safety of vonoprazan. The incidences of any AEs, drug-related AEs, serious AEs, AEs leading to drug discontinuation, and common AEs were pooled. Odds ratios (ORs) were calculated to compare the incidence of AEs between patients taking vonoprazan and PPIs. Results: Seventy-seven studies were included. The pooled incidences of any AEs, drug-related AEs, serious AEs, and AEs leading to drug discontinuation were 20, 7, 1, and 1%, respectively. The incidences of any AEs (OR = 0.96, p = 0.66), drug-related AEs (OR = 1.10, p = 0.44), serious AEs (OR = 1.14, p = 0.36), and AEs leading to drug discontinuation (OR = 1.09, p = 0.55) were not significantly different between patients taking vonoprazan and PPIs. In subgroup analyses, patients with peptic ulcer disease (PUD) had higher incidences of any AEs, serious AEs, and AEs leading to drug discontinuation than those with gastroesophageal reflux disease (GERD), Helicobacter pylori ( H. pylori) infection, and artificial ulcer after gastric endoscopic submucosal dissection (ESD), but patients with H. pylori infection had a higher incidence of drug-related AEs than those with PUD, GERD, and artificial ulcer after gastric ESD. The incidence of AEs was higher in patients taking long-term use of vonoprazan than those taking short-term use of vonoprazan. Conclusion: Vonoprazan is well tolerated and shows similar safety compared to PPIs. The safety of vonoprazan may be primarily influenced by its indications and duration. Registration: PROSPERO CRD42022314982.

show abstract

Section: Resultsmentioning

confidence: 99%

“…These included studies which were published between 2015 and 2022. Seventy-four studies were conducted in Asia, 10–15,19–22,24–28,30–53,55–…”

Section: Resultsmentioning

confidence: 99%

Section: Study Selection and Characteristicsmentioning

confidence: 99%

Section: Study Selection and Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis

Bai

Shang

et al. 2023

Therap Adv Gastroenterol

View full text Add to dashboard Cite

show abstract

“…Vonoprazan is also effective in patients with PPI-resistant esophagitis, inducing healing in some 85% [66,67]. The efficacy of vonoprazan was maintained long term, with post hoc analysis showing lower recurrence rates compared to lansoprazole both in Japan [68] and in other Asian (i.e., China, Malaysia, South Korea, and Taiwan) countries [69].…”

Section: Vonoprazan Efficacy In Erosive Reflux Diseasementioning

confidence: 99%

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Scarpignato

Hunt

2021

Curr Treat Options Gastro

View full text Add to dashboard Cite

Purpose of the review The introduction of H2-receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) into clinical practice has been a real breakthrough in the treatment of acid-related diseases. PPIs are now the standard of care for the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD), Helicobacter pylori infection, NSAID-associated gastroduodenal lesions, and upper gastrointestinal bleeding (UGIB). However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. Recent findings To address these needs, new long-acting compounds (such as tenatoprazole and AGN 201904-Z) and new PPI formulations, including instant release omeprazole (IR-omeprazole) and dexlansoprazole modified release (MR), have been developed. However, a major advance has been the development of the potassium-competitive acid blockers (P-CABs), which block the K+,H+-ATPase potassium channel, are food independent, are reversible, have a rapid onset of action, and maintain a prolonged and consistent elevation of intragastric pH. Vonoprazan and tegoprazan are the two marketed P-CABs while two other compounds (namely fexuprazan and X842) are under active development. Available for almost 6 years now, a considerable experience has been accumulated with vonoprazan, the efficacy and safety of which are detailed in this paper, together with the preliminary results of the other members of this new pharmacologic class. Summary Based on the available evidence, erosive reflux disease, H. pylori infection, and secondary prevention of NSAID gastropathy can be considered established indications for vonoprazan and are being explored for tegoprazan and fexuprazan. In the treatment of severe (LA C & D) reflux esophagitis and H. pylori eradication, vonoprazan proved to be superior to PPIs. Other uses of P-CABs are being evaluated, but clinical data are not yet sufficient to allow a definitive answer on its efficacy and possible superiority over the current standard of care (i.e., PPIs). The most notable indication of upper GI (non-variceal) bleeding, where vonoprazan would prove superior to PPIs, has not yet been explored. The safety of P-CABs in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

show abstract

Tu1321 VONOPRAZAN 10 OR 20 MG DEMONSTRATED SUPERIORITY OVER LANZOPRAZOLE 15 MG IN PREVENTING RELAPSE IN ASIAN PATIENTS WITH ENDOSCOPIC HEALING OF EROSIVE ESOPHAGITIS: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY

Cited by 2 publications

References 0 publications

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis

Incidence and type of adverse events in patients taking vonoprazan: A systematic review and meta-analysis

Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

Contact Info

Product

Resources

About